A Research Guide for
Facing Neuromyelitis Optica Spectrum Disorder

EMA & FDA APPROVED Ravulizumab is a long-acting complement C5 inhibitor dosed every 8 weeks instead of every 2 weeks (eculizumab). The CHAMPION-NMOSD trial demonstrated similar efficacy to eculizumab with the convenience of less frequent infusions. It received EMA approval in May 2023 and FDA approval in March 2024. It is approved for AQP4-IgG seropositive adults in both the EU and the US.

FDA-APPROVED Eculizumab was the first therapy specifically approved for NMOSD (June 2019). It blocks complement protein C5, preventing the complement-mediated destruction of astrocytes that drives NMOSD attacks. The PREVENT trial showed a dramatically reduced annualized relapse rate (ARR 0.02 vs. 0.35 with placebo). Requires meningococcal vaccination before starting due to increased infection risk.

FDA & EC APPROVED Inebilizumab targets CD19 on B cells, providing broader B-cell depletion than rituximab (which targets CD20). The N-MOmentum trial showed a 77% reduction in attacks compared to placebo. Given as IV infusion on days 1 and 15, then every 6 months. FDA-approved June 2020 and EC-approved April 25, 2022, for AQP4-IgG seropositive adults in both the US and EU.

FDA-APPROVED Satralizumab blocks the IL-6 receptor, reducing the inflammatory signaling that drives NMOSD attacks. It can be used as monotherapy or in combination with immunosuppressive therapy. The SAkuraStar and SAkuraSky trials showed significant relapse reduction. Given as a subcutaneous injection at home — at weeks 0, 2, and 4, then every 4 weeks. This self-administered, at-home dosing is a significant practical advantage for many patients.

DIAGNOSTIC ADVANCE The development of cell-based assays for AQP4-IgG antibody detection has transformed NMOSD diagnosis. These assays are more sensitive and specific than older ELISA-based tests. Approximately 70–80% of NMOSD patients test positive. A positive AQP4-IgG result with a core clinical characteristic is sufficient for diagnosis, eliminating the need for dissemination in space and time criteria used in MS.

Aquaporin-4 antibody testing is the single most important diagnostic test for NMOSD. Key points:

• Cell-based assay (CBA) is the gold standard method — significantly more sensitive and specific than older ELISA-based tests. Insist on CBA testing.
• Approximately 70–80% of NMOSD patients are AQP4-IgG seropositive.
• A positive result with one core clinical characteristic (optic neuritis, transverse myelitis, or area postrema syndrome) is sufficient for diagnosis.
• If the first test is negative but suspicion is high, retest. Some patients seroconvert later, and testing during or shortly after high-dose steroids or plasma exchange can produce false negatives.
• Testing is available from: Quest Diagnostics, Mayo Clinic Laboratories, ARUP Laboratories, and specialized neuroimmunology reference laboratories.

Myelin oligodendrocyte glycoprotein (MOG) antibodies identify a different disease — MOG antibody-associated disease (MOGAD). Key differences:

• MOGAD can look like NMOSD clinically but has a generally better prognosis.
• Some patients initially diagnosed with NMOSD turn out to have MOGAD.
• MOGAD may respond differently to treatment — the optimal therapy is still being defined.
• MOG-IgG testing should be performed in all AQP4-IgG seronegative patients with NMOSD-like presentations.
• MOGAD is increasingly recognized as a separate entity from AQP4+ NMOSD.

MRI is essential for evaluating NMOSD attacks and supporting the diagnosis:

• Spinal cord MRI: Longitudinally extensive transverse myelitis (LETM) — lesions extending over 3 or more vertebral segments — is characteristic of NMOSD. This is unusual in MS, where spinal cord lesions are typically shorter.
• Brain MRI: Brain lesions in NMOSD tend to be different from MS. They may involve the area postrema, periependymal regions, hypothalamus, or optic chiasm. NMOSD brain lesions often do not meet MS dissemination in space criteria.
• Orbital MRI: May show optic nerve enhancement extending more than half the nerve length, or involving the optic chiasm — features more typical of NMOSD than MS.

• You have antibodies against aquaporin-4, confirming the autoimmune mechanism.
• All four FDA-approved biologics (eculizumab, ravulizumab, inebilizumab, satralizumab) were specifically approved for AQP4-seropositive patients.
• Relapse prevention therapy should be started as soon as possible after diagnosis.
• The disease course is typically relapsing, and each attack risks cumulative disability.
• Prognosis has dramatically improved with modern biologic therapies.

• You tested negative for AQP4 antibodies. This does not rule out NMOSD, but the diagnosis requires stricter criteria.
• MOG-IgG testing should be performed — you may have MOGAD instead.
• If both AQP4-IgG and MOG-IgG are negative, the diagnosis is “double-seronegative” NMOSD, which is the most diagnostically challenging group.
• FDA-approved biologics were studied primarily in AQP4-seropositive patients, so the evidence for their use in seronegative NMOSD is limited.
• Rituximab, mycophenolate, and azathioprine are commonly used off-label in seronegative patients.
• Repeat AQP4-IgG testing should be considered, especially if the initial test was done during or after immunosuppressive treatment.

• Have you tested me for AQP4-IgG antibodies using a cell-based assay (not just ELISA)?
• If AQP4 is negative, have you tested for MOG-IgG antibodies?
• Could this be NMOSD rather than MS? Have you ruled out NMOSD before starting any MS therapy?
• What do my MRI findings show — are my spinal cord lesions longitudinally extensive?
• Should I be referred to a neuroimmunology specialist with NMOSD experience?
• When should we start relapse prevention therapy?
• Should the AQP4-IgG test be repeated if my initial result was negative?

The first treatment for any NMOSD attack.

• Dose: Methylprednisolone 1,000 mg IV daily for 3–5 days (sometimes up to 7 days in severe attacks)
• Timing: Should be started as soon as possible — ideally within hours of symptom onset
• How it works: High-dose steroids rapidly suppress the inflammatory response attacking the nervous system
• What to expect: Some patients notice improvement during or shortly after the steroid course. Others may need several weeks. Complete recovery is not guaranteed, especially if treatment is delayed.
• Side effects: Insomnia, increased blood sugar, mood changes, metallic taste, stomach irritation. These are temporary.
• Oral taper: A gradual oral prednisone taper over 2–6 weeks often follows IV treatment.

Used when steroids alone are not sufficient, or as initial combination therapy in severe attacks.

• How it works: Blood is withdrawn, the plasma (containing the harmful antibodies) is separated and discarded, and the blood cells are returned with replacement fluid. This physically removes AQP4-IgG antibodies and inflammatory factors.
• Protocol: Typically 5–7 exchanges performed every other day
• When to use: If incomplete response to IVMP after 3–5 days; as initial add-on to IVMP for severe attacks (particularly severe optic neuritis or extensive myelitis); some experts start PLEX simultaneously with IVMP for the most severe presentations
• Evidence: Multiple observational studies support PLEX in NMOSD. Earlier initiation of PLEX is associated with better outcomes.
• Requires: A central venous catheter; performed at centers with apheresis capability

An alternative when PLEX is not available or not feasible.

• Dose: 0.4 g/kg/day IV for 5 days (total 2 g/kg)
• When used: When PLEX is unavailable, when vascular access for PLEX is problematic, or as an additional rescue therapy
• Evidence: Less robust evidence than for PLEX in NMOSD, but may be beneficial in some patients

• How quickly should I come to the ER if I suspect an attack?
• Should I start PLEX at the same time as IV steroids, or wait to see if steroids work first?
• What is the plan if I do not improve after 5 days of IV steroids?
• Is there a written emergency action plan I can carry with me?
• What should I tell ER staff who may not be familiar with NMOSD?
• Should I have a letter from my neurologist explaining my diagnosis and emergency treatment needs?

FDA-APPROVED First FDA-approved therapy for NMOSD (June 2019).

FDA-APPROVED EMA-approved May 2023; FDA-approved March 2024 for NMOSD.

FDA & EC APPROVED FDA-approved June 2020; EC-approved April 2022.

FDA-APPROVED FDA approved August 2020.

OFF-LABEL The most commonly used NMOSD therapy worldwide.

• Mechanism: Targets CD20 on B cells, depleting the cells that produce AQP4-IgG antibodies
• Dosing protocols: 375 mg/m² IV weekly × 4 (lymphoma protocol) OR 1,000 mg IV × 2 doses, 2 weeks apart (RA protocol); re-dosing every 6 months or guided by CD19/CD20 B-cell counts
• Evidence: Multiple open-label studies and retrospective analyses show significant relapse reduction. No randomized controlled trial specifically for NMOSD.
• Advantages: Extensive clinical experience; biosimilars widely available at much lower cost; familiar to most neurologists
• Limitations: Not FDA-approved for NMOSD; infusion reactions (especially first dose); risk of progressive multifocal leukoencephalopathy (PML) is very rare but has been reported; hypogammaglobulinemia with prolonged use
• Cost: Significantly less expensive than FDA-approved biologics, especially with biosimilars

OFF-LABEL

• Mechanism: Blocks IL-6 signaling (similar mechanism to satralizumab but a different antibody)
• Dosing: 8 mg/kg IV every 4 weeks or 162 mg SC weekly
• Evidence: Open-label studies showing significant relapse reduction; more commonly used in Japan and some Asian countries
• Consideration: May be an option when other therapies have failed or are not tolerated

OFF-LABEL

• Mechanism: Suppresses B and T cell proliferation by inhibiting purine synthesis
• Dosing: 1,000–1,500 mg orally twice daily
• Evidence: Retrospective studies show moderate relapse reduction; commonly used as a bridge therapy or in combination with other agents
• Advantages: Oral; relatively inexpensive; widely available
• Limitations: Less effective than biologic therapies; GI side effects; teratogenic (absolutely contraindicated in pregnancy)

OFF-LABEL

• Mechanism: Purine analogue immunosuppressant; suppresses lymphocyte proliferation
• Dosing: 2.5–3 mg/kg/day orally
• TPMT testing: Must check thiopurine methyltransferase (TPMT) activity before starting — TPMT-deficient patients are at high risk of severe bone marrow suppression
• Role: Often used in low- and middle-income countries where it may be the only affordable option; sometimes used as a steroid-sparing agent
• Limitations: Slower onset of action (weeks to months); less effective than biologic therapies

• Which relapse prevention therapy do you recommend for me and why?
• Am I a candidate for an FDA-approved biologic?
• What will my insurance cover? Are there patient assistance programs?
• How is this therapy administered (infusion center vs. home injection)?
• What monitoring or vaccinations do I need before starting?
• If I am on rituximab, should I consider switching to an FDA-approved therapy?
• What happens if I have a breakthrough attack while on prevention therapy?
• How long will I need to stay on this therapy?

• Breakthrough attack: A confirmed NMOSD attack while on adequate relapse prevention therapy is the clearest reason to switch.
• Intolerable side effects: Side effects that significantly impact quality of life.
• Practical barriers: Infusion center access, insurance changes, or preference for different dosing schedule.
• Pregnancy planning: Some therapies are safer than others during pregnancy (see Pregnancy section).
• Inadequate B-cell depletion: For rituximab, persistent CD19/CD20+ B cells despite adequate dosing.

• NMOSD can relapse during pregnancy and postpartum. The postpartum period (first 3–6 months after delivery) carries an especially high relapse risk.
• Mycophenolate mofetil is absolutely contraindicated in pregnancy (Category X teratogen). Must be stopped at least 6 weeks before attempting conception.
• Azathioprine has been used during pregnancy in other autoimmune diseases with reasonable safety data but requires careful risk-benefit discussion.
• Rituximab is typically stopped before conception, though it has been used during pregnancy in some cases. B-cell depletion may persist for months after the last dose, providing some protection.
• Eculizumab and ravulizumab have limited but emerging pregnancy data. Some cases of continued use during pregnancy have been reported. Complement inhibitors may theoretically affect placental complement regulation.
• Satralizumab has limited pregnancy data. IL-6 plays roles in normal pregnancy.
• Pre-conception counseling with both a neuroimmunologist and a maternal-fetal medicine specialist is essential.

• Which relapse prevention therapy is safest to continue during pregnancy?
• How long before conception should I stop my current medication?
• What is the relapse risk during pregnancy and postpartum?
• Should I see a maternal-fetal medicine specialist?
• How will we monitor for attacks during pregnancy?
• What is the plan if I have an attack while pregnant?
• Is breastfeeding safe with my medication?

• Neuro-ophthalmology follow-up is essential for monitoring visual function after optic neuritis.
• Low-vision rehabilitation services can help maximize remaining vision through magnification devices, adaptive technology, and mobility training.
• Optical coherence tomography (OCT) can track retinal nerve fiber layer thickness as a biomarker of optic nerve damage.

• Neuropathic pain is common after transverse myelitis and can be severe and disabling.
• First-line medications: Gabapentin, pregabalin
• Second-line: Duloxetine, amitriptyline (also helps with sleep)
• Other options: Carbamazepine for paroxysmal tonic spasms; topical agents; pain management referral for refractory cases

• Spasticity: Baclofen, tizanidine, or physical therapy stretching programs; botulinum toxin injections for focal spasticity
• Bladder dysfunction: Urodynamic testing to characterize the problem; medications (oxybutynin, mirabegron); intermittent catheterization if needed; urology referral
• Fatigue: Sleep optimization, energy conservation strategies, exercise within tolerance, treatment of contributing factors (depression, pain, sleep disorders)

• Physical therapy: Essential for maintaining and improving mobility, strength, and balance after myelitis attacks
• Occupational therapy: Adapting daily activities, home modifications, assistive devices
• Aquatic therapy: Water-based exercises can be particularly beneficial for patients with spasticity and mobility limitations
• Inpatient rehabilitation: May be appropriate after severe attacks resulting in significant disability

• Asian populations: NMOSD is significantly more prevalent in Japan, Korea, and Southeast Asia, where it represents a larger proportion of CNS demyelinating disease. Both eculizumab and satralizumab were studied in international trials with significant Japanese/Asian enrollment.
• Afro-Caribbean populations: Higher prevalence and often more severe disease course. Access to approved biologics is limited in many African and Caribbean countries.
• Rituximab dominance globally: Due to the extreme cost of approved biologics (eculizumab ~$700,000/year, others $200,000–$400,000/year), rituximab remains the de facto first-line therapy in most low- and middle-income countries.
• Azathioprine and mycophenolate: Often the only available options in countries where even rituximab is inaccessible.
• AQP4-seronegative management differs internationally: Some Asian countries favor NMOSD-specific protocols regardless of serostatus, while some European centers treat seronegative patients with MS-type approaches.

HARMFUL IN NMOSD Interferon-beta is a standard MS therapy but has been repeatedly reported to worsen NMOSD. Multiple case series have documented increased relapse rates and disease severity in NMOSD patients treated with interferon-beta. It should never be used in NMOSD.

HARMFUL IN NMOSD Natalizumab, an anti-alpha4 integrin antibody used in MS, has been associated with worsening or triggering of NMOSD attacks. Case reports of severe relapses after natalizumab initiation in patients later found to have NMOSD have been published. It should not be used in NMOSD.

HARMFUL IN NMOSD Fingolimod has been reported to exacerbate NMOSD. The mechanism may relate to its effects on lymphocyte trafficking that could paradoxically worsen astrocyte-targeted autoimmunity. Other S1P receptor modulators (siponimod, ozanimod) are similarly not recommended in NMOSD.

INSUFFICIENT EVIDENCE / CAUTION Alemtuzumab, an anti-CD52 antibody causing profound lymphocyte depletion, has been used in some NMOSD patients with mixed results. Some case reports suggest benefit, while others describe disease worsening. It is not recommended as a standard NMOSD therapy.

• Know the emergency plan. NMOSD attacks require immediate emergency department visits. Keep a written action plan, diagnosis letter from the neurologist, and list of current medications readily accessible.
• Act fast. If your loved one reports sudden vision changes, new weakness, or intractable vomiting/hiccups, go to the ER immediately. Every hour of delay increases the risk of permanent damage.
• Advocate at the ER. Many ER physicians may not be familiar with NMOSD. Be prepared to explain that NMOSD is not MS, that high-dose IV steroids are needed urgently, and that the patient’s neurologist should be contacted immediately.

• Help arrange low-vision rehabilitation services if optic neuritis has caused permanent visual changes.
• Assist with home modifications for mobility limitations (grab bars, shower chairs, non-slip surfaces).
• Help coordinate physical therapy, occupational therapy, and aquatic therapy appointments.
• Assist with adaptive technology and assistive devices as needed.

• Treatment logistics: Help coordinate infusion appointments, transportation, and medication refills. Some biologics require every-2-week infusions; others are less frequent.
• Emotional support: The unpredictability of NMOSD attacks and the fear of permanent disability take a significant emotional toll. Encourage and support professional counseling or peer support groups.
• Caregiver self-care: Caring for someone with a chronic, relapsing disease is exhausting. Seek your own support through counseling, support groups, and respite care.
• Connect with other NMOSD families: The Guthy-Jackson Charitable Foundation offers resources and community connections for NMOSD families.

• “neuromyelitis optica spectrum disorder treatment 2026”
• “eculizumab NMOSD PREVENT trial”
• “ravulizumab NMOSD CHAMPION”
• “inebilizumab N-MOmentum NMOSD”
• “satralizumab SAkuraStar SAkuraSky”
• “rituximab neuromyelitis optica”
• “AQP4 antibody testing cell-based assay”
• “NMOSD acute attack plasma exchange”

• “rozanolixizumab FcRn NMOSD”
• “nipocalimab FcRn neuromyelitis optica”
• “ublituximab anti-CD20 NMOSD”
• “imlifidase IdeS NMOSD rescue”
• “BTK inhibitor neuromyelitis optica”
• “NMOSD tolerization antigen-specific”
• “MOG antibody-associated disease treatment”